3-deazaguanine, a candidate drug for the chemotherapy of breast carcinomas?
Khwaja, T.A.
Cancer Treatment Reports 66(10): 1853-1858
1982
ISSN/ISBN: 0361-5960 PMID: 7127323 Document Number: 192013
3-Deazaguanine (3-DG) is a new purine antagonist that is active against slow- and rapid-growing solid experimental tumors, especially those that are models for human breast carcinomas. These tumors include mammary adenocarcinomas 13762, R3230AC, and C3H/16C. 3-DG also showed positive activity against leukemias L1210 and L1210/araC, adenocarcinoma 755, and EMT-6 mammary adenocarcinoma. On the basis of its activity against these tumors, 3-DG is to undergo clinical trials.
Document emailed within 1 workday
Related Documents
Hemmer, J.; Kreidler, J.; Kraft, K.; Schön, E. 1994: Monitoring of anticancer drug effects in vivo by serial DNA flow cytometry of oral carcinomas treated by intra-arterial 5-fluorouracil/cisplatin induction chemotherapy Anticancer Research 14(5b): 2077-2083Hegazy, S.K.; El-Azab, G.A.; Zakaria, F.; Mostafa, M.F.; El-Ghoneimy, R.A. 2022: Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer Life Sciences 299: 120536
Regidor, P.A.; Nelken, B.; Regidor, M.; Bier, U.; Oberhoff, C.; Schindler, A.E. 1996: Effectiveness and tolerance of Navoban (5HT3-receptor antagonist tropisetron) in prevention of cytostatic drug-induced nausea and vomiting in patients with breast carcinomas and gynecological malignancies Zentralblatt für Gynakologie 118(3): 148-153
Fushimi, K.; Nakano, S.; Kumagai, K.; Yamamoto, N. 2010: Utility of CPT-11 as salvage chemotherapy for progressive or recurrent breast cancer patients with multiple drug resistance Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(6): 1095-1099
Di Martino, L.; Tarquini, A.; Mitchell, I.; Deshpande, N. 1980: Hormone synthesis by primary breast carcinomas and prognosis in human breast cancer Tumori 66(2): 197-203
Friedrich, M.; Villena-Heinsen, C.; He, J.; Mink, D.; Reichrath, J.; Reitnauer, K.; Schmidt, W. 1998: Correlation between immunoreactivity for transglutaminase K and for markers of proliferation and differentiation in normal breast tissue and breast carcinomas European Journal of Gynaecological Oncology 19(5): 444-448
Moro, K.; Nagahashi, M.; Tsuchida, J.; Tatsuda, K.; Toshikawa, C.; Hasegawa, M.; Ishikawa, T.; Shimada, Y.; Sakata, J.; Kameyama, H.; Kobayashi, T.; Minagawa, M.; Kosugi, S-ichi.; Koyama, Y.; Wakai, T. 2015: Locally Advanced Breast Cancer Treated with Halsted's Operation Because of Drug-Induced Lung Injury Caused by Neoadjuvant Chemotherapy--A Case Report Gan to Kagaku Ryoho. Cancer and ChemoTherapy 42(12): 1803-1805
Pouillart, P.; Schwarzenberg, L.; Palangie, T.; Belpomme, D.; Mathé, G.; Huguenin, P.; Morin, P.; Gautier, H.; Laparre, C.; Baron, A. 1976: Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations La Nouvelle Presse Medicale 5(9 Oct 76: 2145-2150
2006: NIAID researchers make key discovery in development of TB drug candidate Journal of investigative medicine: the official publication of the American Federation for Clinical Research 54(2): 53-54
Culine, S. 2005: Chemotherapy of penile carcinomas Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 15(4 Suppl 2: 829-830
Karrer, K.; Pridun, N.; Zwintz, E. 1975: Chemotherapy of bronchial carcinomas Zeitschrift für Erkrankungen der Atmungsorgane 142(2): 149-163
Roth, S.; Rathert, P. 1991: Chemotherapy of penile carcinomas Der Urologe. Ausg. a 30(1): 10-16
Marino, M.T.; Peggins, J.O.; Brown, L.D.; Urquhart, M.R.; Brewer, T.G. 1994: Pharmacokinetics and kinetic-dynamic modeling of an 8-aminoquinoline candidate anticyanide and antimalarial drug (WR242511) Drug Metabolism and Disposition: the Biological Fate of Chemicals 22(3): 358-366
Chevrel, J.P. 1978: Chemotherapy for digestive carcinomas. General principles La Nouvelle Presse Medicale 7(41): 3749-3752
Zylberberg, B.; Dormont, D.; Ravina, J.H.; Madelenat, P.; Salat-Baroux, J.; Ferrand, G.; Antoine, J.M.; Pennehouat, G. 1991: Ovarian carcinomas. Intraperitoneal chemotherapy by needle Presse Medicale 20(28): 1320-1326
Rainer, H.; Moser, K.; Bettelheim, P. 1978: Randomized study: chemotherapy versus chemotherapy plus transfer factor in metastasized breast neoplasm Verhandlungen der Deutschen Gesellschaft für Innere Medizin 84: 604-606
Tsukuda, M. 2000: Recent regimen of chemotherapy for advanced head and neck carcinomas Gan to Kagaku Ryoho. Cancer and ChemoTherapy 27(3): 341-347
Arnhold-Schneider, M.; Polyzoidis, T. 1987: Critical remarks on the chemotherapy of squamous cell carcinomas of the oropharynx Hno 35(11): 468-471
Goldberg, H.; Tsalik, M.; Bernstein, Z.; Haim, N. 1994: Cisplatin-based chemotherapy for advanced basal and squamous cell carcinomas Harefuah 127(7-8): 217
Strah, K.M.; Love, S.M. 1992: The in situ carcinomas of the breast Journal of the American Medical Women's Association 47(5): 165-168